Other prognostic factors associated with better outcomes with this definitive strategy after treatment to the brain disease are younger age [31,33], early stage nodal disease [15-17,27,28,31], good performance status [18,30-32,34], adenocarcinoma subtype [14,28,32,35], location of primary tumor, site of brain metastases, and low CEA levels [28,36]. This evidence concerns the gene CEACAM5 and adenocarcinoma.